Most Read Articles
22 Jun 2017
Compared with other models of care, nurse-led care (NLC) for patients with rheumatoid arthritis (RA) is effective, acceptable and safe, according to a recent study. However, current evidence is limited to draw conclusions on its accessibility, appropriateness and efficiency.
24 Jun 2017
Sleep disorders commonly occur in patients with ankylosing spondylitis (AS), particularly those with high disease activity, a study has found. Furthermore, treatment with antitumour necrosis factor (anti-TNF)-α improves sleep quality but not polysomnography parameters.
26 Jul 2017
The use of hydroxychloroquine (HCQ) and low-dose aspirin (ASA) appears to improve systemic lupus erythematosus (SLE), according to a recent study. This finding supports its continued use in patients with SLE.
Roshini Claire Anthony, 21 Sep 2016

Patients with rheumatoid arthritis (RA) who did not respond adequately to a tumour necrosis factor α (TNF-α) inhibitor derived better benefit from treatment with a non-TNF-targeted biologic drug over a second anti-TNF drug, a recent study suggested.

Patients with ankylosing spondylitis face long, frequent flares

13 Apr 2017

Flares are common and long in patients with ankylosing spondylitis (AS) before the wide use of biologics, according to a Canada study.

To examine the frequency of patient-reported flares and their related factors, researchers conducted a cross-sectional study using 2004 data of a Canadian cohort with AS according to the modified New York criteria (n=234; mean age 45.5 years; 73.5 percent males).

They assessed the participants’ current flare status (“Are you experiencing a current flare?”), number of flares over the past 3 months, average duration, Bath Ankylosing Spondylitis Disease Activity and Functional Index (BASDAI and BASFI, respectively), and AS Quality of Life questionnaire by self-report. Factors linked to current flare were analysed using univariate and multivariate regressions.

AS patients had a mean disease duration of 21.7 years, and mean BASDAI and BASFI (0 to 10) of 4.4 and 3.4, respectively. There were 18 (7.7 percent) patients who received antitumour necrosis factor (anti-TNF).

Of the analysed patients, 175 (74.8 percent) reported flares and 117 (50 percent) were currently in flare. Those who reported flares had a median of three occurrences in 3 months, with a median duration of 2 weeks. As a whole, all 234 patients spent a median of 25 percent of their time in flare.

Based on multivariate analyses, current flare was significantly associated with higher BASDAI (odds ratio [OR], 2.01; p=0.01), worse quality of life (OR, 1.37; p=0.004), shorter AS duration (OR, 1.19; p=0.04) and less anti-TNF (OR, 7.14; p=0.03).

“As expected, flare was associated with higher disease activity, suggesting the validity of the concept of patient-reported flares,” researchers said.

Editor's Recommendations
Most Read Articles
22 Jun 2017
Compared with other models of care, nurse-led care (NLC) for patients with rheumatoid arthritis (RA) is effective, acceptable and safe, according to a recent study. However, current evidence is limited to draw conclusions on its accessibility, appropriateness and efficiency.
24 Jun 2017
Sleep disorders commonly occur in patients with ankylosing spondylitis (AS), particularly those with high disease activity, a study has found. Furthermore, treatment with antitumour necrosis factor (anti-TNF)-α improves sleep quality but not polysomnography parameters.
26 Jul 2017
The use of hydroxychloroquine (HCQ) and low-dose aspirin (ASA) appears to improve systemic lupus erythematosus (SLE), according to a recent study. This finding supports its continued use in patients with SLE.
Roshini Claire Anthony, 21 Sep 2016

Patients with rheumatoid arthritis (RA) who did not respond adequately to a tumour necrosis factor α (TNF-α) inhibitor derived better benefit from treatment with a non-TNF-targeted biologic drug over a second anti-TNF drug, a recent study suggested.